- Home
- PCRX vs STGW Comparison
PCRX vs STGW Comparison
Compare PCRX & STGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- STGW
- Stock Information
- Founded
- PCRX 2006
- STGW 1980
- Country
- PCRX United States
- STGW United States
- Employees
- PCRX N/A
- STGW N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- STGW
- Sector
- PCRX Health Care
- STGW
- Exchange
- PCRX Nasdaq
- STGW Nasdaq
- Market Cap
- PCRX 1.2B
- STGW 1.2B
- IPO Year
- PCRX 2011
- STGW N/A
- Fundamental
- Price
- PCRX $22.90
- STGW $4.65
- Analyst Decision
- PCRX Buy
- STGW Strong Buy
- Analyst Count
- PCRX 8
- STGW 4
- Target Price
- PCRX $28.38
- STGW $9.13
- AVG Volume (30 Days)
- PCRX 545.0K
- STGW 1.4M
- Earning Date
- PCRX 07-29-2025
- STGW 07-31-2025
- Dividend Yield
- PCRX N/A
- STGW N/A
- EPS Growth
- PCRX N/A
- STGW N/A
- EPS
- PCRX N/A
- STGW N/A
- Revenue
- PCRX $702,772,000.00
- STGW $2,822,897,000.00
- Revenue This Year
- PCRX $7.54
- STGW $4.88
- Revenue Next Year
- PCRX $10.78
- STGW $11.07
- P/E Ratio
- PCRX N/A
- STGW N/A
- Revenue Growth
- PCRX 3.08
- STGW 9.64
- 52 Week Low
- PCRX $11.16
- STGW $4.03
- 52 Week High
- PCRX $27.64
- STGW $8.18
- Technical
- Relative Strength Index (RSI)
- PCRX 35.82
- STGW 51.53
- Support Level
- PCRX $22.82
- STGW $4.48
- Resistance Level
- PCRX $23.83
- STGW $4.67
- Average True Range (ATR)
- PCRX 0.74
- STGW 0.16
- MACD
- PCRX -0.02
- STGW 0.05
- Stochastic Oscillator
- PCRX 6.22
- STGW 82.56
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.